Ontology highlight
ABSTRACT:
SUBMITTER: Cushman WC
PROVIDER: S-EPMC5862000 | biostudies-literature | 2018 Apr
REPOSITORIES: biostudies-literature
Cushman William C WC Bakris George L GL White William B WB Weber Michael A MA Sica Domenic D Roberts Andrew A Lloyd Eric E Kupfer Stuart S
Journal of hypertension 20180401 4
<h4>Background</h4>Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD).<h4>Objective/methods</h4>We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed with an olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily titrated to 40/25 mg if needed in a randomized, double-blind, 8-week stud ...[more]